OneMedNet Adds 2.7M Annual Cardiovascular Studies, Expanding Network

Rhea-AI Summary

OneMedNet (Nasdaq:ONMD) has significantly expanded its Cardiovascular Real-World Data (RWD) network by adding 85 cardiovascular centers and data sources, contributing approximately 2.7 million annual cardiovascular studies. This expansion positions OneMedNet as one of the largest providers of cardiovascular RWD.

The enhanced network provides de-identified cardiovascular imaging, diagnostic reports, and electrocardiograms (ECG) to life sciences companies, AI developers, and medical device manufacturers. This data is particularly valuable given that cardiovascular diseases (CVDs) cause 19.8 million deaths globally and generate $320 billion in annual costs in the US alone.

Positive

• Addition of 85 cardiovascular centers expanding data network coverage
• Positioning as one of the largest providers of Cardiovascular Real-World Data
• Access to large addressable market with CVD generating $320B annually in US costs
• Continuous data updates ensuring current and relevant information for clients

Negative

• None.

Insights

Healthcare Data Analyst

OneMedNet significantly expanded its cardiovascular data network, positioning it as a premier provider of real-world clinical data for healthcare innovation.

OneMedNet has made a strategic expansion of its cardiovascular data network, adding 85 cardiovascular centers that will contribute 2.7 million annual cardiovascular studies to its platform. This positions the company as one of the largest providers of cardiovascular real-world data (RWD) in the industry.

The timing of this expansion is particularly significant given the massive scale of cardiovascular disease burden: CVDs cause 19.8 million deaths annually (representing 32% of global mortality) and generate economic costs of $320 billion in the US and $1 trillion globally.

This expanded network delivers substantial value through de-identified cardiovascular imaging, diagnostic reports, and electrocardiograms (ECGs) at unprecedented scale. The data is continuously updated, making it especially valuable for pharmaceutical companies accelerating R&D efforts, AI developers training specialized algorithms, insurance companies managing risk profiles, and medical device manufacturers seeking regulatory approval.

The real competitive advantage here is the combination of scale, clinical depth, and continuous updating of the data. Most competing data providers offer either breadth or depth, but rarely both with real-time updates. This expansion transforms OneMedNet's offering into a comprehensive ecosystem rather than just a data repository.

For life sciences companies specifically, this expansion provides access to longitudinal patient data that can dramatically reduce time-to-market for new therapies by enabling more targeted research and faster evidence generation for regulatory submissions. The continuously refreshed nature of the data means companies can identify emerging treatment patterns and outcomes much faster than with traditional clinical data sources.

MINNEAPOLIS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD), announced the addition of 85 cardiovascular centers and data sources, expanding its Cardiovascular network thereby positioning OneMedNet as one of the largest providers for Cardiovascular Real-World data.

Cardiovascular diseases (CVDs) remain the world’s leading cause of death, responsible for approximately 19.8 million deaths in 2022, accounting for roughly 32% of all global mortality¹. Economically, the burden is staggering: CVD drives an estimated $320 billion annually in the United States alone, and more than $1 trillion globally each year in direct healthcare costs and lost productivity².

Such pervasive health and financial pressures make OneMedNet’s enriched multimodal cardiovascular data network ideally suited for pharmaceutical and insurance sectors. For drug developers, this real-time, expansive data offers deeper insights into disease progression, treatment responses, and outcomes—fueling more efficient, evidence-based R&D and accelerating the development of novel therapeutics.

This expansion enhances OneMedNet’s network, delivering de-identified cardiovascular imaging, diagnostic reports, and electrocardiograms (ECG) at unprecedented scale and clinical depth to life sciences companies, AI developers, and medical device manufacturers, with data that is continually updated to reflect the latest clinical insights and advancements.

The addition of these new sites solidifies OneMedNet’s position as the premier source for high-quality, regulatory-grade cardiovascular RWD, fueling innovation, supporting clinical evidence generation, and improving patient outcomes through the most robust ecosystem in the industry.

“By combining de-identified cardiovascular imaging, structured reports, and ECG signals from this vast network, we’re providing real-world clinical insights that accelerate innovation in diagnostics, therapeutics, and AI model development. This is the clinically rich, longitudinal data the industry has been demanding—and we’re delivering it at scale, with continual updates ensuring the most current and relevant information,” said Aaron Green, President and CEO of OneMedNet.

1. World Health Organization Cardiovascular Disease – https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-%28cvds%29
2. World Heart Federation 2025 Report - https://world-heart-federation.org/resource/world-heart-report-2025/

About OneMedNet Corporation

OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,750 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.

Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. We base these forward-looking statements on our current expectations and projections about future events, which we derive from the information presently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.

OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com

FAQ

What expansion did OneMedNet (ONMD) announce in August 2025?

OneMedNet announced the addition of 85 cardiovascular centers and data sources, expanding its Cardiovascular network and positioning itself as one of the largest providers for Cardiovascular Real-World Data.

How large is the cardiovascular disease market that OneMedNet (ONMD) is targeting?

The cardiovascular disease market generates $320 billion annually in the United States and more than $1 trillion globally in direct healthcare costs and lost productivity.

What type of data does OneMedNet (ONMD) provide through its cardiovascular network?

OneMedNet provides de-identified cardiovascular imaging, diagnostic reports, and electrocardiograms (ECG) to life sciences companies, AI developers, and medical device manufacturers.

Who are the main customers for OneMedNet's (ONMD) cardiovascular data?

The main customers are pharmaceutical companies, insurance sectors, life sciences companies, AI developers, and medical device manufacturers who use the data for R&D, clinical evidence generation, and innovation.